On May 13, 2021, Ann D. Rhoads resigned from the Board of Directors of Evoke Pharma, Inc. Ms. Rhoads advised the company that her decision to resign was not the result of any disagreement with the company or its management on any matter relating to the company's operations, policies or practices. Additionally, on May 13, 2021, pursuant to the bylaws of the company, the Board appointed Vickie Reed to fill the vacancy created by such resignation. Ms. Reed will serve as a Class III director, with an initial term expiring at the company's 2022 annual meeting of stockholders. In addition, in connection with Ms. Rhoads' resignation and the Board appointment of Ms. Reed, effective as of May 13, 2021, the Audit Committee of the Board is composed of Todd C. Brady, M.D., Ph.D., Kenneth J. Widder, M.D. and Ms. Reed, who will serve as chair of the Audit Committee, and the Compensation Committee of the Board is composed of Dr. Brady, Cam L. Garner, and Malcolm R. Hill, Pharm.D., and Mr. Garner will continue to serve as chair of the Compensation Committee. Ms. Reed currently serves as Senior Vice President and Chief Accounting Officer of Mirati Therapeutics, Inc., a position she had held since January 2020. Previously, Ms. Reed served as Vice President of Finance of Mirati Therapeutics, Inc. from December 2016 through January 2020, and as Senior Director, Controller from October 2013 through December 2016.
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
EVOKE PHARMA, INC. 
